News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

ZEUS – Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

Study Status:

Not Yet Recruiting

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

The purpose of this study is to determine if ziltivekimab (administered subcutaneously) reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.

Information: 

Principal Investigator
Mahesh Changlani, MD
Sponsor
Novo Nordisk A/S
Type of Trial
Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank